Sanofi’s Multiple Sclerosis Drug Slows Disease’s Progression
Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom there’s currently no treatment.
Key biomarkers identified for predicting disability progression in multiple sclerosis
A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple sclerosis (MS). The breakthrough research has the potential to transform treatment strategies for millions of MS patients worldwide,
Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows
Sanofi reports positive phase 3 HERCULES study data for tolebrutinib in non-relapsing secondary progressive multiple sclerosis, showing a 31% delay in disability progression. Study also revealed increased disability improvement,
Biomarkers for predicting multiple sclerosis progression identified
Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the development of more personalized treatment strategies.
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.
Sanofi’s eyes approval after MS therapy slows disease progression by 31%
After missing primary endpoints in relapsing forms of MS, tolebrutinib has proved its efficacy in secondary progressive MS patients.
MedPage Today13h
Women With MS Less Likely to Receive Treatment Than Men
Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...
FierceBiotech1d
Sanofi lifts lid on MS data behind tolebrutinib’s mixed phase 3 scorecard, plans ‘24 approval filings
Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...
Medscape1d
High-Dose Vitamin D Linked to Lower Disease Activity in CIS
Vitamin D is linked to a 34% reduction in the relative risk for disease activity in patients with clinically isolated ...
Medpage Today on MSN4d
Higher Comorbidity Burden in Multiple Sclerosis Tied to Worse Outcomes
Higher comorbidity burden among people with multiple sclerosis (MS) was associated with worse clinical outcomes, pooled trial ...
PHILADELPHIA.Today on MSN1d
Local Multiple Sclerosis Advocate Honored With State Citation
Bucks County resident Joseph “Smiley” Terinoni was recently presented with a citation from the Pennsylvania House of ...
STAT8d
FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug
Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...
MedPage Today on MSN1d
Kids With MS May Have Better Outcomes When Started on High-Efficacy Treatment Early
Among 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late ...
Medscape8d
Does Multiple Sclerosis Protect Against Alzheimer's?
Patients with MS showed half the rate of amyloid pathology compared with people without MS, suggesting a possible protective ...